MedPath

Doxazosin

These highlights do not include all the information needed to use DOXAZOSIN TABLETS safely and effectively. See full prescribing information for DOXAZOSIN TABLETS. DOXAZOSIN tablets, for oral useInitial U.S. Approval: 1990

Approved
Approval ID

b4c974ad-cbd6-4811-ab48-461e7ffa99f7

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 3, 2023

Manufacturers
FDA

A-S Medication Solutions

DUNS: 830016429

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Doxazosin Mesylate

PRODUCT DETAILS

NDC Product Code50090-6298
Application NumberANDA209013
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateJuly 31, 2021
Generic NameDoxazosin Mesylate

INGREDIENTS (6)

DOXAZOSIN MESYLATEActive
Quantity: 4 mg in 1 1
Code: 86P6PQK0MU
Classification: ACTIM
anhydrous lactoseInactive
Code: 3SY5LH9PMK
Classification: IACT
magnesium stearateInactive
Code: 70097M6I30
Classification: IACT
microcrystalline celluloseInactive
Code: OP1R32D61U
Classification: IACT
sodium lauryl sulfateInactive
Code: 368GB5141J
Classification: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Doxazosin - FDA Drug Approval Details